Work title

Full Name

Alan Slade joined ITBMed in January 2019 and has over 15+ years of experience in global drug development across Phase I – III.  Alan holds a Doctor of Pharmacy from Purdue University and completed a Post-Doc Fellowship in clinical pharmacology with Rutgers University.  His development experience has primarily been on immunosuppression and immunomodulation in solid-organ transplantation as well as rheumatology, ophthalmology and nephrology.
Alan is the inventor on several patents and has authored over 30 publications and book chapters in the field of transplantation and nephrology.  Prior to joining ITBMed, Alan was with Novartis Pharmaceuticals, most recently as Director, Clinical Development for Transplantation and Rheumatology responsible for Phase II-IV clinical development and submissions for both novel and marketed compounds in transplantation, autoimmunity and autoinflammatory indications.

Senior VP, Global Head Clinical Development

Alan Slade

Anna-Karin joined ITBMed in 2019 as a Financial Controller and has over 20 years of experience in finance, leadership and administration in various industries, mainly in smaller as well as major international listed group companies. She has a degree in management &amp; finance and in addition to this, she is also a certified coach.

Financial Controller

Anna-Karin Lindblad

Britain graduated from Georgetown University with a Master’s in Physiology. Prior to joining ITBMed in 2021, Britain worked primarily in phase II and III clinical trials at Weill Cornell Medicine.

Associate Clinical Trial Manager

Britain Javens

David Berglund, M.D., Ph.D., M.B.A., is an Associate Professor of Immunology that has published more than 40 peer-reviewed articles in areas ranging from transplant immunology and oncology to transfusion medicine and biomaterials. David also received clinical training in transplant and reconstructive plastic surgery at Uppsala University Hospital and Karolinska University Hospital in Sweden. He has worked with drug development for more than 10 years focusing on strategic leadership of both early- and late-stage pharmaceutical companies. David holds an M.B.A. from NYU Stern School of Business with specializations in Corporate Finance and Leadership &amp; Change Management.

Founder & President 

David Berglund

Elizabeth holds a bachelor’s degree in Biochemistry &amp; Molecular and Cellular Biology from the University of Arizona. Prior to joining ITBMed in September 2022, Elizabeth worked as a clinical laboratory technologist, specializing in molecular diagnostic testing.

Clinical Research Associate

Elizabeth Boulter

Elma holds a Master´s in Experimental and Medical Bioscience for Linköping University in Sweden. Elma joined ITB-MED in August 2022 and has experience across all drug development phases but has mainly worked with phase II and III clinical trials. Most recently she worked with clinical trial start-ups as a Clinical Operations Manager at Merck.

Elma Redzic

Erik Berglund, M.D., Ph.D., is an Associate Professor of Transplantation Surgery with extensive drug discovery and clinical development experience. Dr. Berglund´s expertise spans therapeutic areas including transplantation surgery, tolerance induction, xenotransplantation, autoimmunity, immuno-oncology, machine perfusion and biomaterials. He has authored more than 35 peer-reviewed publications and 16 patents.
Trained at Karolinska Institute and Karolinska University Hospital, Dr. Berglund specialized in transplantation surgery, immunology, and oncology. He has served on the faculty of Columbia University Center for Translational Immunology, has been a member of the scientific committee for the European Society for Organ Transplantation, and has consulted the European Commission and Swedish Government on transplantation. Dr. Berglund earned both his medical and doctorate degrees from Karolinska Institute, has been the recipient of multiple awards, and is a frequently hired speaker. With over 12 years in drug development, he has contributed to several early and late-stage pharmaceutical companies as a founding executive and strategic advisor.

CEO & Founder

Erik Berglund

Filip Cvetkovski received a BSc in Molecular Biotechnology from Heidelberg University, Germany, and a PhD in Microbiology and Immunology from Columbia University in New York. Filip has over ten years of research experience in immunology and animal models of human disease.

Laboratory Director Research and Development

Filip Cvetkovski

Fredrik holds a Master of Science in Pharmacy, University of Uppsala and has 25 years of experience from Clinical Operations, including big pharma companies, large CRO and Biotech start-up. Fredrik has worked in all phases of clinical trials and has led both local, regional and global clinical studies. Fredrik joined ITB-MED in January 2023 and most recently come from a Clinical Study Lead/Director role at Calliditas Therapeutics AB.

Clinical Operations Director

Fredrik Juhlin

Jesse holds a Master’s of Public Health and Applied Epidemiology and a Bachelor’s in Molecular and Cellular Biology from the University of Arizona. Jesse joined ITBMed in September 2021 after working for Banner Health, Tucson Medical Center, and the Arizona Trauma Association.

Jesse Scott

M.Sc. in Business and Economics, Finance from Stockholm University. Kasper was appointed CFO in 2018 but has been working with ITBMed as an external finance consultant since the company was founded in 2016. Prior to joining ITBMed Kasper has worked with corporate finance in Stockholm and has experience from IPOs, equity and debt financings as well as M&amp;A transactions.

Chief Financial Officer

Kasper Granlund

Kellie holds a Bachelor´s Degree in Nursing from the University of Michigan and has over twenty years of clinical operations experience. Kellie joined ITBMed in February 2019 and has experience across all drug development phases in large and small pharma. Most recently she worked as Director Clinical Operations at Axsome Therapeutics. Kellie has also worked for Asklepion Pharmaceuticals, Pfizer Inc., PPD, and Kendle International.

Executive Director, Head of Clinical Operations

Kellie Kennon

Leslie has 20+ years of life sciences legal and compliance experience.  He has served as the General Counsel and Chief Compliance Officer for publicly-traded and privately held biopharmaceutical companies.  His legal, strategic, transactional, intellectual property and compliance experience spans the research, development, approval, launch and commercialization of innovative products.  Leslie holds a juris doctor degree from the University of Florida.

Chief Legal and Compliance Officer

Leslie Zacks

Lindsey holds a Master’s degree in Clinical Research Administration from George Washington University (GWU). Prior to joining ITBMed in November 2022, Lindsey worked as a Clinical Research Coordinator for the GWU Medical Faculty Associates, and most recently as a Human Subjects Research Protections Analyst supporting the US Department of Homeland Security.

Clinical Trial Associate

Lindsey Dickerson

Lovisa Ringstad, PhD in Pharmacy from Uppsala University, has 15 years of experience in pharmaceutical research and development, project management and CMC from research institutes and industry. Lovisa joined ITB-MED in August 2023 and most recently come from a role as Head of CMC at Ilya Pharma AB.

Global CMC Regulatory Affairs, Associate Director

Lovisa Ringstad

Marsha Miller, MS, PhD joined ITBMed in July 2022 and brings nearly 25 years of pharmaceutical industry experience in global regulatory affairs spanning all phases of drug development. Prior to joining ITBMed, she served as an Executive Director and Team Lead in global regulatory affairs at Bristol Myers Squibb providing strategic regulatory guidance and leadership to teams developing products in immunology, neurology and fibrosis.
Marsha has also held global regulatory positions with increasing responsibilities at Celgene, Sanofi and AstraZeneca in support of development activities and health authority approvals for products in a variety of therapeutic areas and indications including metabolic and cardiovascular diseases, rheumatology, and gastroenterology. Marsha holds a PhD in Pathology from the University of Pennsylvania, an MS in Chemistry from Lehigh University, and a BS in Chemistry and Biology from the University of Pittsburgh.

VP, Head of Regulatory Affairs

Marsha Miller

Mikael has an educational background in Biotechnology Engineering from KTH Royal Institute of Technology. Prior to joining ITBMed, Mikael worked at a CRO, most recently as an IT Manager overseeing the company’s IT expansion from a start-up to a scale-up.

IT Manager

Mikael Holmqvist

Miriam Casacuberta holds a PhD in Biomedicine from the Leiden University Medical Centre in the Netherlands. Prior to joining ITB-MED in June 2023, Miriam worked in interventional studies in human parasitology, both in the Netherlands and Ivory Coast.

Miriam Casacuberta-Partal

Nick joined ITBMed in October 2019 with 10+ years of experience in clinical operations within clinical monitoring and trial management in both large CROs and small biopharmaceutical companies. Most recently Nick worked for Axsome Therapeutics as a Sr. Clinical Trial Manager where he was responsible for the oversight of several phase 2/3 programs.

Associate Director

Nick Hryciw

Peter Frank, M.Sc in engineering working over 15 years with CMC as Senior Scientist, production manager&amp;project manager. Previously positioned as CMC project Manager for DS&amp;DP in biologics including clinical trial manufacturing as well as constructing and implementing a commercial DS and aseptic DP manufacturing facility.

Head of CMC

Peter Frank

Sara holds a Master of Science degree in Biology from Linköpings university and have 15 years of experience from clinical research both from Pharmaceutical and CRO companies. Sara Joined ITB-MED in August 2023 and came from a role as director of clinical operations from a Biotech start-up company.

Clinical Trial Manager

Sara Lavasani

Stefan Berg has broad experience from leading positions in the pharmaceutical industry, including drug discovery and development, and business development. He has previously served as Associate Director and Discovery Project Leader, AstraZeneca AB; Executive Vice President, Northern Light Pharmaceuticals AB; Project Director at Karolinska Institutet Science Park AB. Stefan has filed more than 40 patent applications and has authored around 15 publications and book chapters. Stefan has worked within different indications e.g immunology, cancer, neuroscience, psychology and pain.

Head of Supply Chain Management & Logistics and Founder

Stefan Berg

Susanne joined ITBMed in October 2018 and tends to HR &amp; Workplace matters within the organization. She is also responsible for handling the day-to-day operations in the Stockholm office. She has extensive experience from various administrative roles in different industries.

HR & Workplace Manager

Susanne Svärd

Terese joined ITBMed in 2022 as an Accountant, working mostly with Accounts Payables and Legal Administration. She has extensive experience from finance and administration from various industries, mainly in smaller and midsized companies in both the private as well as the public sector.

Accountant

Terese Bylund

Our team has a long experience from pharmaceutical research and development, business development, entrepreneurship, transplantation surgery and immunology. We are located across two continents covering the global operations.

Join us now

We’re developing an innovative therapy that would potentially empower transplant patients to reclaim their freedom and quality of life – all without the need for immunosuppressive medications.

Meet the team

Help us make a real difference